ArticleAntimicrobial resistance and infection control2026
The present and the future of antimicrobial resistance surveillance in Catalonia (Spain), 2024: from manual to automatic notification.
Article in Antimicrobial resistance and infection control, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance (AMR) remains a major global public health concern requiring coordinated surveillance and technological innovation. In Catalonia, AMR surveillance is conducted through the Microbiological Reporting System of Catalonia (MRSC) and will be integrated into the Epidemiological Surveillance Information System (SIVEC), enabling automated and real-time monitoring. This study aimed to evaluate the current landscape of AMR surveillance and laboratory capacity across clinical microbiology laboratories (CMLs).
methodsAll CMLs participating in the MRSC were invited to complete a structured survey assessing diagnostic capacity, resistance mechanism (RM) detection, laboratory information systems (LIS), and reporting practices. Surveillance data from invasive isolates (one per patient and episode) collected between 2016 and 2023 were analysed. CMLs were classified by complexity (L1-L3) according to phenotypic, molecular and genomic capabilities. Temporal trends in resistance were assessed using logistic regression models.
resultsBy 2023, 53 CMLs participated compared with 28 in 2016, reflecting a marked increase in coverage. A total of 87,556 invasive isolates and 694,289 susceptibility tests were reported. Escherichia coli was the most frequently notified microorganism (37,999 isolates), followed by Klebsiella pneumoniae (12,626) and methicillin-susceptible Staphylococcus aureus (10,464). All laboratories followed EUCAST criteria, although only 56.6% had implemented the 2023 version. Most CMLs (92.5%) detected RMs and 73.6% monitored multidrug resistance. Based on complexity, 18.9% were L1, 66.0% L2, and 15.1% L3; most notifications were reported by L2 (57.4%) and L3 laboratories (39.4%). Carbapenem resistance decreased in Pseudomonas aeruginosa (21.7 to 12.9%) and K. pneumoniae (6.3% to 3.2%), whereas E. coli increased (0.07 to 0.52%). Vancomycin resistance increased in Enterococcus faecium (0.27 to 2.30%) and remained low in E. faecalis. Third-generation cephalosporin resistance increased in E. coli (14.4 to 17.8%) and decreased in K. pneumoniae (36.0 to 26.6%), while MRSA declined (33.1 to 20.6%).
conclusionsAMR surveillance in Catalonia provides robust and representative data across a heterogeneous network. Further efforts are needed to ensure consistent EUCAST implementation and expand RM detection. The implementation of SIVEC will enable integrated, real-time surveillance and support timely, evidence-based public health decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.